What Happened?
Shares of insulin delivery company Insulet Corporation (NASDAQ: PODD) jumped 5.6% in the afternoon session after the company posted strong fourth-quarter 2025 financial results that beat Wall Street's expectations.
The company reported fourth-quarter revenue of $783.8 million, up 31.2% from the previous year and surpassing analyst estimates. This growth was driven by strong demand for its Omnipod insulin management systems. Insulet's profitability also impressed, with adjusted earnings of $1.55 per share, which was 6% above consensus projections. Looking ahead, the company provided a positive outlook, guiding for a 26% year-over-year sales increase for the first quarter of 2026, which was roughly in line with what analysts were expecting.
Is now the time to buy Insulet? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Insulet’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 9 months ago when the stock gained 20.7% on the news that the company reported strong first quarter 2025 results which significantly beat analysts' constant currency revenue, EPS, and EBITDA expectations. Its quarterly revenue guidance also outperformed Wall Street's estimates. The key number was a 30% jump in constant currency sales, led by strong growth in the U.S. and a big push overseas, where Omnipod sales rose 36%. Zooming out, we think this was a solid print.
Insulet is down 7.9% since the beginning of the year, and at $260.57 per share, it is trading 26.1% below its 52-week high of $352.82 from September 2025. Investors who bought $1,000 worth of Insulet’s shares 5 years ago would now be looking at an investment worth $953.37.
While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report, it’s free.
